Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 182

1.

Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.

Sanabria A, Chaves AL, Kowalski LP, Wolf GT, Saba NF, Forastiere AA, Beitler JJ, Nibu KI, Bradford CR, Suárez C, Rodrigo JP, Strojan P, Rinaldo A, de Bree R, Haigentz M Jr, Takes RP, Ferlito A.

Auris Nasus Larynx. 2017 Feb;44(1):18-25. doi: 10.1016/j.anl.2016.06.005. Epub 2016 Jul 5. Review.

PMID:
27397024
2.
3.

Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.

Marur S, Forastiere AA.

Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. Review.

PMID:
26944243
4.

Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes.

Forastiere AA, Weber RS, Trotti A.

J Clin Oncol. 2015 Oct 10;33(29):3262-8. doi: 10.1200/JCO.2015.61.2978. Epub 2015 Sep 8. Review.

5.

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.

Kelly RJ, Forde PM, Elnahal SM, Forastiere AA, Rosner GL, Smith TJ.

J Oncol Pract. 2015 Jul;11(4):308-12. doi: 10.1200/JOP.2015.003780. Epub 2015 May 26.

6.

Quality of care and short- and long-term outcomes of laryngeal cancer care in the elderly.

Gourin CG, Starmer HM, Herbert RJ, Frick KD, Forastiere AA, Quon H, Eisele DW, Dy SM.

Laryngoscope. 2015 Oct;125(10):2323-9. doi: 10.1002/lary.25378. Epub 2015 May 22.

PMID:
26010671
7.

Short- and long-term outcomes of laryngeal cancer care in the elderly.

Gourin CG, Starmer HM, Herbert RJ, Frick KD, Forastiere AA, Eisele DW, Quon H.

Laryngoscope. 2015 Apr;125(4):924-33. doi: 10.1002/lary.25012. Epub 2014 Nov 4.

PMID:
25367258
8.

Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R.

Hum Genet. 2015 May;134(5):497-507. doi: 10.1007/s00439-014-1470-0. Epub 2014 Aug 10.

9.

Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA.

Clin Cancer Res. 2014 Oct 1;20(19):5041-51. doi: 10.1158/1078-0432.CCR-14-0051. Epub 2014 Aug 8.

10.

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB.

Ann Oncol. 2014 Nov;25(11):2230-6. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31. Erratum in: Ann Oncol. 2015 May;26(5):1038-9.

11.

Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).

Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA.

Ann Oncol. 2014 Oct;25(10):2036-41. doi: 10.1093/annonc/mdu248. Epub 2014 Jul 9.

12.

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R.

Ann Oncol. 2014 Jul;25(7):1410-6. doi: 10.1093/annonc/mdu167. Epub 2014 May 5.

13.

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA.

Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3.

14.

When is chemotherapy in head and neck squamous cell carcinoma not indicated?

Haigentz M Jr, Vermorken JB, Forastiere AA, Corry J, Beitler JJ, Strojan P, Hartl DM, Rodrigo JP, Bradford CR, Rinaldo A, Takes RP, Mendenhall WM, Shaha AR, Wolf GT, Ferlito A.

Eur Arch Otorhinolaryngol. 2015 Apr;272(4):781-7. doi: 10.1007/s00405-014-2894-9. Epub 2014 Feb 14. No abstract available.

PMID:
24525999
15.

Treatment, survival, and costs of laryngeal cancer care in the elderly.

Gourin CG, Dy SM, Herbert RJ, Blackford AL, Quon H, Forastiere AA, Eisele DW, Frick KD.

Laryngoscope. 2014 Aug;124(8):1827-35. doi: 10.1002/lary.24574. Epub 2014 Feb 11.

PMID:
24515616
16.

Quality indicators of laryngeal cancer care in the elderly.

Gourin CG, Frick KD, Blackford AL, Herbert RJ, Quon H, Forastiere AA, Eisele DW, Dy SM.

Laryngoscope. 2014 Sep;124(9):2049-56. doi: 10.1002/lary.24593. Epub 2014 Feb 22.

PMID:
24431293
17.

Reply to e.g. Russi et Al and R. Haddad.

Forastiere AA, Zhang Q, Weber RS, Ridge JA.

J Clin Oncol. 2013 Sep 1;31(25):3171. doi: 10.1200/JCO.2013.50.7137. Epub 2013 Jul 29. No abstract available.

PMID:
23943828
18.

Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question.

Forastiere AA, Adelstein DJ, Manola J.

J Clin Oncol. 2013 Aug 10;31(23):2844-6. doi: 10.1200/JCO.2013.50.3136. Epub 2013 Jul 8. No abstract available.

PMID:
23835711
19.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators..

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
20.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

Supplemental Content

Loading ...
Support Center